AstraZeneca Pauses COVID-19 Vaccine Trials
As part of the ongoing randomized, controlled clinical trials of the AstraZeneca Oxford coronavirus vaccine, AZD1222, a standard review process has been triggered, leading to the voluntary pause of vaccination across all trials to allow an independent committee to review the safety data of a single event of an unexplained illness that occurred in the UK Phase III trial. Read more...
RedHill Biopharma’s Opaganib Demonstrates Complete Inhibition of SARS-CoV-2
RedHill Biopharma announced opaganib demonstrated potent inhibition of SARS-CoV-2, the virus that causes COVID-19, achieving complete blockage of viral replication in an in vitro model of human lung bronchial tissue. Read more...
Celularity Doses First Patient in Trial Evaluating CYNK-001 in COVID-19 Patients
Celularity announced the first patient was dosed in a Phase I/II study of human placental hematopoietic stem cell derived NK cells (CYNK-001) for the treatment of adults with COVID-19 as part of a national clinical trial. Read more...
Small Study Shows Convalescent Plasma Safe in COVID-19 Pediatric Patients
Early findings from researchers at Children's Hospital of Philadelphia (CHOP) show that convalescent plasma appears to be a safe and possibly effective treatment for children with life-threatening cases of COVID-19. Read more...